AtonRa Partners’s Kymera Therapeutics KYMR Stock Holding History

AtonRa Partners’s Portfolio KYMR Stock Details KYMR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$428K	Sell	16,808 -2,364	-12%	-$42.3K	0.85%	48
2023 Q3	$266K	Sell	19,172 -2,775	-13%	-$55.8K	0.56%	87
2023 Q2	$505K	Sell	21,947 -1,832	-8%	-$52.5K	0.78%	56
2023 Q1	$705K	Sell	23,779 -3,346	-12%	-$108K	1.03%	30
2022 Q4	$677K	Sell	27,125 -7,337	-21%	-$196K	0.86%	50
2022 Q3	$750K	Sell	34,462 -134	-0.4%	-$3.53K	0.74%	61
2022 Q2	$681K	Sell	34,596 -17,368	-33%	-$406K	0.63%	74
2022 Q1	$2.2M	Buy	51,964 +4,235	+9%	+$179K	1.19%	31
2021 Q4	$3.03M	Buy	47,729 +17,641	+59%	+$1.03M	1.05%	37
2021 Q3	$1.77M	Buy	30,088 +3,130	+12%	+$181K	0.59%	68
2021 Q2	$1.31M	Buy	+26,958	New	+$1.17M	0.48%	76

Other funds holding KYMR

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AtonRa Partners's KYMR Position: Q4 2023 in Review

AtonRa Partners reduced its Kymera Therapeutics (KYMR) stake by 12% in Q4 2023, selling an estimated $42.3K and leaving 16,808 shares worth $428K. The position accounts for 0.85% of the portfolio, ranked #48.

AtonRa Partners first reported a position in KYMR in Q2 2021 and has held it in 11 quarters since. The position peaked at $3.03M in Q4 2021. 136 funds tracked by Wall St. Rank hold KYMR as of Q4 2023.

AtonRa Partners held 16,808 shares of Kymera Therapeutics worth $428K as of Q4 2023.
AtonRa Partners sold 2,364 Kymera Therapeutics shares in Q4 2023, an estimated $42.3K.
Kymera Therapeutics made up 0.85% of AtonRa Partners's portfolio in Q4 2023, its #48 holding.
AtonRa Partners first reported a position in Kymera Therapeutics in Q2 2021 and has held it in 11 quarters since.
AtonRa Partners's Kymera Therapeutics position peaked at $3.03M in Q4 2021.
136 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q4 2023.

Based on AtonRa Partners's 13F filing for Q4 2023, filed 5 Feb 2024.